Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Dr. Chamie Interview - Quilt 3.032 study (N-803 + BCG)

<< Previous

Bullboard Posts

Next >>

Comment by Eoganachton Apr 20, 2023 3:58pm

172 Views

Post# 35406005

RE:RE:RE:RE:Dr. Chamie Interview - Quilt 3.032 study (N-803 + BCG)

From the chart DJDawg found we can see that not many of the 13 out of 82 patients (16%) who brought the CR at any time rate up from 55% to 71%, by being retreated after recurrence, benefited much from the exercise. 8 of the 13 eventually experienced high-grade recurrences and 1 was lost to follow up either through death or withdrawal from the trial for another reason. Only 4 of these patients, 5%, ended up with a durable response 15 months into the trial.

<< Previous

Bullboard Posts

Next >>

5 steps to mastering risk management in the stock market